SPY330.65-3.85 -1.15%
DIA276.52-2.38 -0.85%
IXIC10,793.28-117.00 -1.07%

Revance Therapeutics Q1 EPS $(1.150) Misses $(0.900) Estimate

Revance Therapeutics (NASDAQ:RVNC) reported quarterly losses of $(1.150) per share which missed the analyst consensus estimate of $(0.900) by 27.78 percent. This is a 35.29 percent decrease over losses of $(0.850) per

Benzinga · 05/07/2020 20:12

Revance Therapeutics (NASDAQ:RVNC) reported quarterly losses of $(1.150) per share which missed the analyst consensus estimate of $(0.900) by 27.78 percent. This is a 35.29 percent decrease over losses of $(0.850) per share from the same period last year.